Introduction: Survivors of severe COVID-19 (Coronavirus Disease 2019) frequently experience long-term functional impairment, a condition known as post-COVID syndrome. As these patients may eventually ...
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ ...
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback